Business Context and Reporting Period
Company: Ovid Therapeutics Inc. (OVID)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Ovid is a clinical-stage biopharmaceutical company developing small molecule medicines for brain disorders, specifically targeting neuronal hyperexcitability in epilepsies and psychoses. The company has no approved products and generates revenue primarily through licensing and royalty agreements.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $7,252 | $566 |
| Net Loss | $(17,414) | $(26,433) |
| Operating Expenses | $49,691 | $62,451 |
| Cash, Cash Equivalents & Marketable Securities | $90,447 | $53,075 |
| Accumulated Deficit | $(321,713) | $(304,299) |
| Net Cash Used in Operating Activities | $(38,334) | $(55,956) |
Liquidity: As of December 31, 2025, the company held $90.4 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least 12 months from the filing date.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased by $6.7 million (1,181%) to $7.3 million, driven primarily by a $7.0 million one-time payment received in June 2025 from an amendment to the Marinus Pharmaceuticals license agreement.
- Reduced Net Loss: Net loss improved by $9.0 million to $17.4 million. This improvement was largely due to a $21.0 million unrealized gain on a long-term equity investment (Graviton Bioscience) and a $1.8 million gain from the recovery of funds previously lost to a business email compromise.
- Expense Reduction: Total operating expenses decreased by $12.8 million. Research and Development (R&D) expenses dropped $11.2 million, primarily due to the pause of the OV888 (GV101) program in late 2024 and reduced payroll costs following a 2024 restructuring.
- Financing Activity: In October 2025, the company completed a private placement raising $75.1 million in net proceeds through the sale of Series B Preferred Stock and warrants.
Guidance, Outlook, and Risks
Outlook and Catalysts
- Pipeline Progress: The company is advancing OV329 (GABA-AT inhibitor) into Phase 2 trials for focal onset seizures, tuberous sclerosis complex (TSC), and infantile spasms. OV4071 (KCC2 activator) received regulatory approval in March 2026 to initiate Phase 1 trials in Australia.
- Capital Needs: The company expects to incur significant operating losses for the foreseeable future. It anticipates needing additional capital to fund clinical trials and operations beyond the current 12-month runway.
- Recent Financing: In March 2026, the company entered into an agreement for a $60.0 million private placement to support the expansion of OV329 development.
Risks and Contingencies
- Internal Controls: The company previously identified material weaknesses in internal controls related to fund transfers following a $1.8 million fraudulent transfer in 2024. These were remediated as of December 31, 2024.
- Regulatory and Clinical Risk: Success depends on clinical trial results and regulatory approvals, which are uncertain. The company has no approved products.
- Market Volatility: The stock price has been volatile, ranging from $0.26 to $1.84 in 2025. The company transferred its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market in August 2025 due to minimum bid price requirements.
- Dependence on Partners: The company relies on third parties for manufacturing and clinical trials. It also depends on milestone payments from partners (e.g., Takeda, AstraZeneca) which are contingent on future events.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $90.4 million cash balance against the projected burn rate, considering the upcoming Phase 2 trials for OV329 and Phase 1 for OV4071.
- Revenue Quality: Confirm that the $7.3 million revenue is non-recurring (one-time Marinus payment) and does not reflect sustainable product sales.
- Equity Dilution: Assess the dilution impact of the October 2025 private placement (Series B Preferred Stock and warrants) and the March 2026 private placement.
- Internal Controls: Review the status of remediation for the previously identified material weaknesses in internal controls over financial reporting.
- Investment Valuation: Scrutinize the $21.0 million unrealized gain on the Graviton Bioscience equity investment, as this is a non-cash item that significantly reduced the reported net loss.